Emergent BioSolutions (EBS) announced it has received a delivery order valued at up to $21.5M from the U.S. Department of War to supply BioThrax in 2026. This order is under Emergent’s existing indefinite-delivery/indefinite-quantity contract, led by the Capability Program Executive Chemical, Biological, Radiological and Nuclear Defense, previously the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense, in collaboration with the Defense Health Agency. Deliveries under this order will take place in 2026. This order includes a one-year base period, with two additional option periods for 2027 and 2028.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions: Strategic Infectious Disease Positioning and Countermeasure Demand Support Buy Rating and $15 Target
- Emergent BioSolutions enters collaboration agreement with PANTHER
- Emergent BioSolutions Receives Buy Rating Amid Strategic Milestones and Strong Market Position
- Emergent BioSolutions Gains FDA Approval for Winnipeg Facility
- Emergent BioSolutions receives FDA approval for raxibacumab manufacturing